Literature DB >> 19665437

What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis.

J Abbott1, A Holt, A Hart, A M Morton, L MacDougall, M Pogson, G Milne, H C Rodgers, S P Conway.   

Abstract

BACKGROUND: There is no standardised definition of a pulmonary exacerbation in cystic fibrosis (CF). In attempting to achieve standardised criteria it is important to identify patient-reported indicators.
METHODS: Interviews were undertaken with 47 adults with CF. Participants were asked to report symptoms experienced during a pulmonary exacerbation in two ways: the first symptoms they become aware of, and how they subsequently recognised when they were improving.
RESULTS: A range of systemic and respiratory symptoms were reported. Their relative importance varied by severity of disease. The severity and subsequent improvement of an exacerbation was often described as limitations on their activities.
CONCLUSION: These preliminary data suggest that patient-reported indicators of a pulmonary exacerbation may not be the same for all adults with CF. Whether different indicators are associated with specific demographic or clinical variables remains to be evaluated.

Entities:  

Mesh:

Year:  2009        PMID: 19665437     DOI: 10.1016/j.jcf.2009.07.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

Review 1.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

2.  What is hepcidin telling us about the natural history of cystic fibrosis?

Authors:  A H Gifford
Journal:  J Cyst Fibros       Date:  2014-04-30       Impact factor: 5.482

3.  Iron and CF-related anemia: expanding clinical and biochemical relationships.

Authors:  A H Gifford; S D Miller; B P Jackson; T H Hampton; G A O'Toole; B A Stanton; H W Parker
Journal:  Pediatr Pulmonol       Date:  2010-10-20

4.  Iron homeostasis during cystic fibrosis pulmonary exacerbation.

Authors:  Alex H Gifford; Lisa A Moulton; Dana B Dorman; Gordana Olbina; Mark Westerman; H Worth Parker; Bruce A Stanton; George A O'Toole
Journal:  Clin Transl Sci       Date:  2012-06-01       Impact factor: 4.689

5.  The use of ivacaftor in CFTR mutations resulting in residual functioning protein.

Authors:  S Guigui; J Wang; R I Cohen
Journal:  Respir Med Case Rep       Date:  2016-10-18

6.  Corticosteroid-resistant inflammatory signalling in Pseudomonas-infected bronchial cells.

Authors:  Mirai Mizutani; Julie Bérubé; Heather G Ahlgren; Joanie Bernier; Elias Matouk; Dao Nguyen; Simon Rousseau
Journal:  ERJ Open Res       Date:  2017-06-19

7.  C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations.

Authors:  Elias Matouk; Dao Nguyen; Andrea Benedetti; Joanie Bernier; James Gruber; Jennifer Landry; Simon Rousseau; Heather G Ahlgren; Larry C Lands; Gabriella Wojewodka; Danuta Radzioch
Journal:  J Pulm Respir Med       Date:  2016-10-14

8.  Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis.

Authors:  Perrine Soret; Louise-Eva Vandenborght; Florence Francis; Noémie Coron; Raphael Enaud; Marta Avalos; Thierry Schaeverbeke; Patrick Berger; Michael Fayon; Rodolphe Thiebaut; Laurence Delhaes
Journal:  Sci Rep       Date:  2020-02-27       Impact factor: 4.379

9.  Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus.

Authors:  Kathleen McElhone; Janice Abbott; Chris Sutton; Montana Mullen; Peter Lanyon; Anisur Rahman; Chee-Seng Yee; Mohammed Akil; Ian N Bruce; Yasmeen Ahmad; Caroline Gordon; Lee-Suan Teh
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-09-02       Impact factor: 4.794

10.  The burden of cystic fibrosis in the Medicaid population.

Authors:  Mariam Hassan; Machaon M Bonafede; Brendan L Limone; Paul Hodgkins; Gregory S Sawicki
Journal:  Clinicoecon Outcomes Res       Date:  2018-07-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.